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Epidermal Langerhans Cells Rapidly Capture and
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Barbara Del Frari2, Franz Koch1, Chae Gyu Park3, Ralph M. Steinman3, Juliana Idoyaga3
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Antigen-presenting cells can capture antigens that are deposited in the skin, including vaccines
given subcutaneously. These include different dendritic cells (DCs) such as epidermal Langerhans cells (LCs),
dermal DCs, and dermal langerinþ DCs. To evaluate access of dermal antigens to skin DCs, we used mAb
to two C-type lectin endocytic receptors, DEC-205/CD205 and langerin/CD207. When applied to murine and
human skin explant cultures, these mAbs were efficiently taken up by epidermal LCs. In addition, anti-DEC-205
targeted langerinþ CD103þ and langerin CD103 mouse dermal DCs. Unexpectedly, intradermal injection
of either mAb, but not isotype control, resulted in strong and rapid labeling of LCs in situ, implying that
large molecules can diffuse through the basement membrane into the epidermis. Epidermal LCs targeted
in vivo by ovalbumin-coupled anti-DEC-205 potently presented antigen to CD4þ and CD8þ T cells in vitro.
However, to our surprise, LCs targeted through langerin were unable to trigger T-cell proliferation.
Thus, epidermal LCs have a major function in uptake of lectin-binding antibodies under standard
vaccination conditions.
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INTRODUCTION
Dendritic cells (DCs) are specialized to take up and
present antigens, a feature now being considered in the
design of vaccines (Steinman and Banchereau, 2007).
Cutaneous DCs, including epidermal Langerhans cells (LCs)
and dermal DCs, are ideally positioned to take up skin-
administered vaccines, process them, and carry them to the
draining lymph nodes, where they stimulate antigen-specific
T cells (Romani et al., 2006). The immunogenic potential of
LCs in vivo depends on the dose and localization of the
antigen (Bennett et al., 2007; Stoitzner et al., 2008; Wang
et al., 2008).
C-type lectin receptors facilitate uptake and processing of
antigenic proteins, and this ability has been exploited to
improve immune responses by targeting antigens to DCs
(Tacken et al., 2007). The best-studied example is DEC-205/
CD205, which is expressed at highest levels by select subsets
of DCs (Henri et al., 2001). When protein antigens are
coupled to anti-DEC-205 mAbs and mice are immunized
with these conjugates in the presence of DC-activating
agents, T-cell-dependent immune responses (Hawiger et al.,
2001; Bonifaz et al., 2004; Boscardin et al., 2006) are
dramatically enhanced in vivo.
Langerin/CD207 is another C-type lectin, specifi-
cally expressed in the skin by epidermal LCs and by a recen-
tly described subset of mouse dermal DCs (Valladeau et al.,
2000, 2002; Kaplan et al., 2008). Antigen targeting by anti-
langerin mAb also results in efficient presentation to CD4þ
and CD8þ T cells in vivo (Idoyaga et al., 2008).
In many of the above-cited studies, immunization with
anti-DEC-205 conjugates was performed by subcutaneous
injection into the footpad. However, despite extensive
research performed with anti-DEC-205 mAbs, it has not been
studied whether cutaneous DEC-205þ DCs participate in
uptake and transport of targeting mAb (Bonifaz et al., 2004;
Carter et al., 2006). This question appears important in view
of the differential functions that epidermal LCs, dermal DCs,
and lymph node-resident DCs seem to have (Allan et al.,
2006; Kissenpfennig and Malissen, 2006). Therefore, we
examined in more detail in situ uptake and handling of
mAbs against C-type lectins by skin DCs, and, surprisingly,
observed that intradermal mAbs are captured by epider-
mal LCs.
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RESULTS
LCs in situ are specifically targeted by mAbs in murine skin
explant cultures
Epidermal LCs and dermal langerinþ DCs express DEC-205
and langerin (Kraal et al., 1986; Valladeau et al., 2002;
Stoitzner et al., 2003; Kaplan et al., 2008), whereas other
dermal DCs lack langerin and display low levels of DEC-205
(Henri et al., 2001). The density of langerinþ cells in the
undisturbed dermis was about 5% of LC density in the
epidermis (B50–80 vs B1000 per mm2 in BALB/c). Dermal
langerinþ cells are emigrating epidermal LCs (Stoitzner et al.,
2003) as well as DCs that reside in the dermis (Kaplan et al.,
2008).
To determine if these DC subsets would capture anti-
receptor antibodies (Abs), we cultured whole-skin explants
from BALB/c mice for different time periods in hybridoma
supernatant NLDC145 (anti-DEC-205) or control nonreactive
IgG2a, LODNP16. Then, epidermal and dermal sheets were
prepared. Labeling was evident on epidermal LCs within
30 minutes with NLDC145, was brightest after 2–4 hours, and
persisted at least 48 hours (Figure 1a). Conversely, no binding
to LCs was evident with LODNP16 (Figure 1b). Similar rapid
targeting was observed when anti-langerin Ab L31 was used,
and equivalent labeling was seen with whole skin from BALB/
c and C57BL/6 mice (Figure 1c).
In keeping with the absence of DEC-205 staining in the
dermis (Kraal et al., 1986), dermal cells that had taken up
anti-DEC-205 mAb were rarely observed before 18 hours of
culture (Figure 1a, bottom; arrowheads). At time points
beyond 18 hours, NLDC145 was detected in considerably
more dermal cells. Many of them were arranged in typical
‘‘cords,’’ which represent dermal lymphatic vessels filled
with migratory LCs (Stoitzner et al., 2003) (Figure 1a, bottom;
arrowheads).
Migratory skin DCs transport anti-DEC-205 and
anti-langerin mAb after ex vivo targeting
To extend our in situ observations, we analyzed by FACS
migratory cells from whole-skin explants that had been
preincubated in targeting mAb for 3 hours, washed exten-
sively, then returned to culture to allow DCs to ‘‘crawl out’’
of the explants. In addition to anti-DEC-205, we used L31, a
new mAb to langerin. As opposed to 929F3 mAb, which
recognizes an intracellular domain of langerin, L31 binds to
the extracellular carbohydrate-recognition domain (Cheong
et al., 2007; Idoyaga et al., 2008).
More than 85% of the migratory cells expressed langerin
(Figure 2a). NLDC145 was primarily taken up by langerinþ
cells, with the exception of a small langerin population
(B5% of all migratory cells; Figure 2a, right panel, arrow).
As expected, L31 targeting mAb was exclusively detected
on langerinþ cells, albeit at lower levels than NLDC145.
Of note, the levels of the targeting mAb decreased with time
in culture, possibly resulting from a degradation of endo-
cytosed mAb (day 2 vs day 4; data not shown).
To investigate the relative contributions of epidermal LCs
and dermal langerinþ DCs, we also studied expression of
CD103, an integrin selectively expressed by the latter sub-
set (Kaplan et al., 2008). A small proportion (3.5% ±0.9;
n¼5) of migratory cells expressed langerin and CD103;
these were efficiently targeted by anti-DEC-205 (Figure 2b).
Among langerin migratory cells, which most likely originate
in the dermis, only CD103 DCs bore the targeting mAb to
DEC-205.
Epidermal LCs are specifically targeted in vivo by
mAb injected intradermally
To examine whether targeting mAb would also reach
epidermal LCs in a standard immunization procedure, we
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Figure 1. Langerhans cells in situ are specifically targeted by mAb in murine skin explant cultures. (a) Whole-skin explants from BALB/c mice were
incubated for 30 minutes to 48 hours in culture medium containing NLDC145 (anti-mouse DEC-205) hybridoma supernatant. Epidermis was then separated
from dermis, fixed, and targeting mAb was revealed with anti-rat IgG secondary Ab. Arrowheads indicate dermal cells targeted in situ. Arrows point at DC-filled
dermal lymphatic vessels. (b) Whole-skin explants from BALB/c mice were incubated for 18 hours in culture medium containing NLDC145 or LODNP16
(isotype control) hybridoma supernatants, then epidermis was separated, fixed, and stained with anti-rat IgG Ab. (c) Whole-skin explants from BALB/c or
C57BL/6 mice were incubated for 4 hours with 5 mg ml1 of purified mAb NLDC145 (anti-mouse DEC-205) or L31 (anti-mouse langerin), then epidermis
was separated, fixed, and stained with anti-rat IgG Ab. Bar¼ 100mm. Results are representative of three independent experiments.
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prepared epidermal sheets 18 hours after intradermal injec-
tion. As little as 0.2 mg of purified NLDC145 was sufficient to
visualize epidermal LCs in situ 18 hours after intradermal
injection (Figure 3a). For further experiments, we injected
1 mg to obtain a brighter staining. No staining could be
observed with IgG2a isotype control (Figure 3b). Interest-
ingly, L31 and NLDC145 were still detectable on LCs for up
to 5 days, although labeling was clearly weaker at this late
time point (Figure 3b).
Next, we used langerin/mice (Kissenpfennig et al.,
2005), which have a normal distribution of epidermal major
histocompatibility complex class IIþ LCs (Figure 3c, top). As
anticipated, langerin/ LCs showed normal binding of
intradermally injected anti-DEC-205 mAb, but failed to be
targeted by anti-langerin L31 mAb (Figure 3c, bottom).
Finally, whole-skin explants were prepared 4 hours after
intradermal injection of targeting mAb, washed in phosphate-
buffered saline (PBS), and cultured for 3 days. Langerinþ DCs
that had been targeted in vivo retained detectable amounts of
the L31 and NLDC145 targeting mAb after migrating out of
skin explants (Figure 3d). Targeting intensity was more
pronounced for NLDC145, and it declined markedly
with time for both targeting mAb (day 2 vs. day 4; data not
shown).
Epidermal LCs present DEC-205-targeted antigen after
in vivo uptake
We next evaluated antigen presentation by epidermal LCs
targeted in vivo. To achieve this, we used Ab coupled to the
model antigen ovalbumin (OVA) and recognizing langerin
(L31/OVA), DEC-205 (aDEC/OVA), and an isotype-matched
control (Ig/OVA). At 4 hours after intradermal injection of 50
or 500 ng of targeting Ab, we prepared LCs by culturing
epidermal sheets for 3 days. Migratory cells consisted largely
of LCs (40.6±2.1%; n¼36). Other cells in the suspension
were T cells and keratinocytes, which are devoid of DEC-205
or langerin (data not shown). Migratory LCs were cultured for
4 days at different ratios with carboxyfluorescein succini-
midyl ester (CFSE)-labeled, OVA-specific CD4þ or CD8þ
T cells from OT-II or OT-I mice, respectively. Proliferation
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Figure 2. Langerhans cells and dermal dendritic cells migrating out of murine skin explants transport the targeting mAb. Whole-skin explants were incubated
for 3 hours in medium containing L31 (anti-langerin), NLDC145 (anti-DEC-205), or IgG2a isotype control, washed in PBS and cultured for 3 days.
Targeting mAb was detected in permeabilized migratory cells by anti-rat IgG Ab. Cells were counterstained with (a) 929F3 mAb to an epitope on the
cytosolic domain of langerin or (b) 929F3 anti-langerin plus anti-CD103. Migratory cell subsets were gated as depicted in the density plot on the left,
and percentages (average ± SEM) of each population are shown in the table below. Histograms display staining intensity of the targeting mAb on the four
different subsets. Filled histograms, IgG2a; empty histograms, anti-DEC-205. Results are representative of three independent experiments.
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was evaluated by the percentage of T cells exhibiting
decreased CFSE staining.
Presentation to CD4þ T cells occurred only when aDEC/
OVA was the targeting reagent (Figure 4a). With 500 ng of Ab
per ear, OVA-specific CD8þ T cells proliferated when
cultured with LCs targeted with any OVA-coupled mAb
(Figure 4b). As these mAbs are mouse IgG1, this unexpected
result likely reflects uptake by Fc-g receptor I (Romani et al.,
1989), which is probably sufficient for antigen presentation
given the extremely high sensitivity of CD8þ T cells from OT-
I mice (Choi et al., 2009). Still, the use of aDEC/OVA, but not
L31/OVA, led to antigen cross-presentation that was sig-
nificantly stronger than with Ig/OVA control. Moreover,
when the injected dose was titrated down to 50 ng per ear,
only targeting with aDEC/OVA allowed LCs to present to
CD8þ T cells (Figure 4c).
Human skin DCs bind and transport anti-DEC-205
and anti-langerin mAb
Finally, we extended our observations to human skin DC
subsets, which we targeted in situ in whole-skin explant
cultures. After 4 days, we observed three distinct populations
of migratory DCs targeted by anti-human DEC-205 mAb,
CD1aneg/low, CD1aþ , and CD1ahigh cells (Figure 5, top). Anti-
DEC-205 was absent (or very low) on a proportion of the
CD1aneg/low cells. Only CD1ahigh DCs could bind anti-
langerin mAb, indicating that they are actually LCs, whereas
CD1aþ langerin and CD1a langerin DCs (Figure 5,
bottom) probably originate in the dermis (Ebner et al., 2004).
DISCUSSION
Targeting antigens to DCs with the help of specific mAbs has
great potential for the development of effective vaccines
(Tacken et al., 2007). We found that anti-langerin and anti-
DEC-205 mAbs are captured in a selective manner by mouse
and human skin DCs, and that targeted DCs carry mAbs
when leaving the skin. Fc receptor-mediated uptake by LCs
could be formally excluded, as shown by the lack of binding
of nonspecific control mAbs in wild-type mice and of anti-
langerin mAbs in langerin/ mice.
Both anti-langerin and anti-DEC-205 were taken up by
epidermal LCs within minutes after intradermal injection.
This indicates that even large immunoglobulins (150 kDa)
can easily diffuse from the dermis through the basement
membrane into the epidermis and gain access to LCs. Of
note, the density of LCs in the epidermal sheets remained
roughly unchanged, showing that intradermal injection of
targeting mAbs in PBS did not result in a degree of
inflammation that would have enhanced emigration of LCs.
Moreover, targeting mAb persisted on LCs for several days,
suggesting that their degradation occurs very slowly after
in vivo uptake. This remarkable property implies that targeted
DCs constitute a pool of antigen-presenting cells that could
be exploited throughout an extended period.
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Figure 3. Langerhans cells are targeted within the epidermis after intradermal injection of anti-lectin Ab in vivo. Different targeting mAbs were injected
intradermally into the ear skin of C57BL/6 mice. Epidermal sheets were prepared 18 hours after injection of 0.2, 1, or 5 mg of NLDC145 (a) and 24 hours or
5 days after injection of 1mg IgG2a, L31, or NLDC145 (b) The capture of the injected mAb was visualized with anti-rat IgG Ab. (c) 18 Hours after injection
of 1mg targeting mAb, major histocompatibility complex class II (upper panel) and targeting mAb (lower panel) were revealed on epidermal sheets from
langerin/ mice. (d) At 4 hours after injection of 1 mg targeting mAb into ear skin of BALB/c mice, whole-skin explants were cultured for 3 days. The targeting
mAb was detected in permeabilized migratory cells (gated on langerinþ cells; mAb 929F3). Filled histograms, IgG2a; empty histograms, mAb as indicated.
Bar¼100 mm. Results are representative of three independent experiments.
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In the mouse, the main target of anti-DEC-205 was
epidermal LCs. In skin explant cultures, targeting mAb were
able to access LsC in the epidermis, whereas relatively few
dermal DCs acquired mAbs. However, due to the relatively
high background staining of the dermis, we could not
exclude the existence of targeted dermal DCs displaying
only low levels of NLDC145 in situ. In fact, when migratory
cells were analyzed by flow cytometry, langerin CD103
and langerinþ CD103þ dermal DC subsets had also
internalized anti-DEC-205, albeit to a much lower extent in
terms of quantity and cell numbers, respectively.
In parallel, human skin explant cultures also revealed
efficient labeling of human skin DCs by anti-lectin mAb.
Targeting of epidermal LCs was achieved by both anti-
langerin and anti-DEC-205 mAb, whereas two distinct DC
populations exclusively bound anti-DEC-205. We did not
further investigate these two subsets, because human dermal
DCs remain less well defined, and their phenotype and
distribution differ markedly from what is observed in a
murine system (Ebner et al., 2004; Tacken et al., 2007; Zaba
et al., 2008). Nevertheless, our findings suffice to indicate
that mAb injected into human skin would efficiently target
skin DCs, including LCs in situ.
Finally, in vivo targeted epidermal LCs were able to pre-
sent the model antigen OVA coupled to anti-DEC-205. As
already proposed in the literature, targeting through DEC-205
appeared to preferentially lead to cross-presentation to CD8þ
T cells, whereas only limited CD4þ T-cell proliferation could
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Figure 4. Langerhans cells present DEC-205-targeted antigen after in vivo uptake. At 4 hours after intradermal injection of 500 ng (a, b) or 50 ng (c) of
OVA-coupled anti-DEC-205, anti-langerin, or isotype control, epidermal sheets were prepared and cultured for 3 days. Migratory epidermal LCs were then
cocultured with CFSE-labeled CD4þ (a) or CD8þ (b, c) T cells purified from OT-II or OT-I mice, respectively. After 4 days, T-cell proliferation was evaluated
by dilution of CFSE. Graphs show T-cell proliferation observed at different LC/T ratios; results from three to six independent experiments are shown. Density
plots display representative FACS stainings for two different LC/T ratios. Asterisks indicate proliferation rates significantly different (Po0.05) from those of
cocultures performed at the same T/LC ratio with Ig/OVA-loaded LCs.
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be induced (Dudziak et al., 2007). Most intriguingly, LCs
could not efficiently present to CD4þ or CD8þ T cells
in vitro when OVA was targeted through langerin, even
though L31/OVA injection does induce proliferation of
transferred OVA-specific T cells in vivo (Idoyaga et al.,
2008). Of note, our in vitro culture system exclusively yields
epidermal LCs. This raises interesting questions about dermal
langerinþ DC subsets, where the fate of antigens internalized
by langerin may differ as compared with LCs. This may be
reflected by the presence or absence of langerinþ Birbeck
granules (Douillard et al., 2005) that are a characteristic
compartment of epidermal LCs, but were not yet examined in
langerinþ dermal DCs.
Maturation probably influences antigen uptake and
processing by C-type lectin-targeted DCs, thereby control-
ling the outcome of T-cell responses. For example, target-
ing through DEC-205 in vivo results in efficient immune
responses only when Abs are provided together with
adjuvants known to induce DC maturation (Hawiger et al.,
2001). However, migratory epidermal LC are already highly
mature cells (Stoitzner et al., 2003), making it difficult, if not
impossible, to further enhance their activation state. Despite
this, we cannot exclude qualitative differences in the
maturation that depend on the activation signal. In parti-
cular, regarding langerin targeting, tissue damage, which is
the likely trigger for LC maturation and migration in our
cultures of epidermal sheets, may not be sufficient for
presentation of antigens internalized into langerinþ compart-
ments.
We have identified epidermal LCs as potent targets of
C-type lectin-binding Abs in human and murine skin.
Nevertheless, other DC subsets appear to be involved as
well. The complex interactions between different DC popu-
lations in the skin, but also in skin-draining lymph nodes,
call for detailed in vivo investigations. Hence, our future
work will focus on resolving these issues, by defining the
functional roles of targeted skin DC in cutaneous immune
responses in vivo.
MATERIALS AND METHODS
Mice
Inbred BALB/c, C57BL/6, OT-I, and OT-II mice were purchased from
Charles River Laboratories (Sulzfeld, Germany) and used at 2–10
months of age. Langerin-deficient mice (Kissenpfennig et al., 2005)
were kindly supplied by S. Saeland. All experimental protocols were
approved by the Austrian Federal Ministry of Science and Research,
Department for Genetic Engineering and Animal Experimentation
(66.011/16-II/106/2008).
Media and reagents
Complete culture medium was Roswell Park Memorial Institute-
1640 supplemented with 10% heat-inactivated fetal calf serum,
2 mM L-glutamine (Sigma, St Louis, MO), 50 mg ml1 gentamicin
(PAA, Linz, Austria), and 50 mM b-mercaptoethanol. Targeting
by rat mAb was detected in situ by goat anti-rat IgG/FITC (BD-
Biosciences, San Diego, CA), or chicken anti-rat IgG/Alexa 594
(Invitrogen, Eugene, OR). For FACS analyses, permeabilization
was performed with Cytofix/perm (BD-Biosciences), and targeting
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Figure 5. Human skin dendritic cells bind and transport targeting mAbs. Human whole-skin explants were incubated for 4 hours in medium containing
DCGM4 (anti-langerin), MG38 (anti-DEC-205), or IgG1 isotype control, then cultured for 4 days. Targeting mAbs were detected in permeabilized migratory
cells by means of anti-mouse IgG secondary Ab. Cells were counterstained with anti-CD1a or anti-langerin. ND, not determined. Results are representative
of two independent experiments.
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mAb was detected with goat anti-rat IgG/APC in murine samples, or
rat anti-mouse IgG/APC in human samples (BD-Biosciences). For
analyses of murine cells, we used mAb to major histocompatibility
complex class II (anti-I-A/I-Ediverse, clone 2G9), CD103 (clone M290)
(BD-Biosciences), and langerin (clone 929F3; Dendritics, Lyon,
France), whereas human cells were stained with mAb to CD1a
(clone HI149; BD-Biosciences) or langerin (clone DCGM4;
Dendritics).
Targeting mAb
L31 mAb recognizing an extracellular portion of murine langerin
was used to target langerin as described (Cheong et al., 2007), and
NLDC145 mAb (BMA Biomedicals, Augst, Switzerland) to target
murine DEC-205 (Kraal et al., 1986). Control mAb was rat IgG2a
(R&D Systems, Minneapolis, MN). OVA-coupled anti-langerin
(L31/OVA), anti-DEC-205 (aDEC/OVA), or isotype-matched control
(Ig/OVA; derived from mouse IgG1) were used in OVA-specific
T-cell proliferation assays (Idoyaga et al., 2008). Human skin cells
were targeted by anti-human DEC-205 (clone MG38) (Guo et al.,
2000) or anti-human langerin (clone DCGM4) (Valladeau et al.,
2000). Mouse IgG1 (BD-Biosciences) was used as isotype control.
Determination of the density of dermal langerinþ cells in situ
Numbers were determined on dermal sheet specimens from several
different C57BL/6 and BALB/c mice, stained by anti-langerin mAb
(929F3), and revealed by secondary goat-anti-rat Ig conjugated to
Alexa 594. In total, langerinþ cells in 40 randomly selected
microscopical fields were counted and areal density determined
by means of a calibrated ocular grid.
Mouse skin explant culture and in vitro targeting experiments
Briefly, mice were killed, ears were cut off at the base, and ear
skin was split into dorsal and ventral halves (Stoitzner et al., 2003).
The dorsal halves were cultured in 24-well plates (one per well), for
the indicated periods, in complete culture medium containing
10% (v/v) of hybridoma supernatants (NLDC145, or LODNP16/
IgG2a isotype control). Finally, epidermal and dermal sheets were
separated with ammonium thiocyanate and fixed in acetone.
For cell migration experiments, ear skin explants from BALB/c
mice were exposed to 5mg ml1 targeting mAb (IgG2a, L31, or
NLDC145) for 3 hours at 37 1C, then extensively washed in PBS,
to avoid binding of targeting mAbs to migratory cells outside of the
skin. Explants were further cultured in complete medium without
chemokines. After 2–4 days, emigrant DCs were harvested and
investigated by flow cytometry.
Alternatively, 4 hours after in vivo targeting (see below),
epidermis was separated from dermis with dispase and cultured for
3 days. LCs present in the migratory epidermal cell suspensions were
quantified and used in T-cell proliferation assays.
In vivo targeting experiments
Purified rat IgG2a, L31, NLDC145, Ig/OVA, L31/OVA, or aDEC/
OVA (0.05–5 mg) diluted in 25 ml PBS were injected into the ear
pinna of anesthetized C57BL/6 or langerin/ mice.
In vitro T-cell proliferation assays
OVA-specific T cells were obtained by MACS purification (Miltenyi
Biotec, Bergisch Gladbach, Germany) of CD4þ and CD8þ T cells
from lymphoid organs of OT-II and OT-I mice, respectively. Purified
T cells were labeled by CFSE, and seeded in round-bottom
microwells (50,000 T cells per well). In vivo targeted LCs, obtained
from a 3-day culture of epidermis alone (see above), were added
at different T/LC ratios. After 4 days of culture, we monitored by
FACS the proportion of T cells exhibiting CFSE dilution, which
allowed us to evaluate the extent of proliferation. Background pro-
liferation of OT-I and OT-II cells cultured alone was below 0.5% in
every experiment (data not shown).
Human skin explant culture and in vitro targeting experiments
Healthy human split-thickness skin was obtained from plastic
surgery (Ebner et al., 2004), in accordance with the Declaration of
Helsinki Principles. Whole-skin explants were floated on culture
medium containing 5mg ml1 targeting mAbs (IgG1, DCGM4, and
MG38) for 3 hours at 37 1C. Then, explants were thoroughly washed
in PBS and cultured in six-well plates. After 4 days, emigrant DCs
were harvested and investigated by FACS.
Statistical analyses
Experiments were performed at least three times with similar results.
Error bars are standard error of the mean. P-values are from two-
tailed Student’s t-tests.
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